Toll Free: 1-888-928-9744
Published: May, 2015 | Pages:
38 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Richter Gedeon Nyrt. - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'Richter Gedeon Nyrt. - Product Pipeline Review - 2015', provides an overview of the Richter Gedeon Nyrt.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Richter Gedeon Nyrt.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Richter Gedeon Nyrt. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Richter Gedeon Nyrt.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Richter Gedeon Nyrt.'s pipeline products Reasons to buy - Evaluate Richter Gedeon Nyrt.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Richter Gedeon Nyrt. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Richter Gedeon Nyrt.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Richter Gedeon Nyrt. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Richter Gedeon Nyrt. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Explore the dormant and discontinued projects of Richter Gedeon Nyrt. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Richter Gedeon Nyrt. Snapshot 5 Richter Gedeon Nyrt. Overview 5 Key Information 5 Key Facts 5 Richter Gedeon Nyrt. - Research and Development Overview 6 Key Therapeutic Areas 6 Richter Gedeon Nyrt. - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Richter Gedeon Nyrt. - Pipeline Products Glance 10 Richter Gedeon Nyrt. - Late Stage Pipeline Products 10 Pre-Registration Products/Combination Treatment Modalities 10 Phase III Products/Combination Treatment Modalities 11 Richter Gedeon Nyrt. - Clinical Stage Pipeline Products 12 Phase II Products/Combination Treatment Modalities 12 Richter Gedeon Nyrt. - Early Stage Pipeline Products 13 Preclinical Products/Combination Treatment Modalities 13 Discovery Products/Combination Treatment Modalities 14 Richter Gedeon Nyrt. - Unknown Stage Pipeline Products 15 Unknown Products/Combination Treatment Modalities 15 Richter Gedeon Nyrt. - Drug Profiles 16 cariprazine 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 pegfilgrastim 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 Small Molecule for Undisclosed Indication 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 rituximab biosimilar 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 trastuzumab biosimilar 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 teriparatide biosimilar 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Richter Gedeon Nyrt. - Pipeline Analysis 23 Richter Gedeon Nyrt. - Pipeline Products by Target 23 Richter Gedeon Nyrt. - Pipeline Products by Route of Administration 24 Richter Gedeon Nyrt. - Pipeline Products by Molecule Type 25 Richter Gedeon Nyrt. - Pipeline Products by Mechanism of Action 26 Richter Gedeon Nyrt. - Recent Pipeline Updates 27 Richter Gedeon Nyrt. - Dormant Projects 31 Richter Gedeon Nyrt. - Discontinued Pipeline Products 32 Discontinued Pipeline Product Profiles 32 radiprodil 32 RGH-512 32 Richter Gedeon Nyrt. - Company Statement 33 Richter Gedeon Nyrt. - Locations And Subsidiaries 34 Head Office 34 Other Locations & Subsidiaries 34 Appendix 37 Methodology 37 Coverage 37 Secondary Research 37 Primary Research 37 Expert Panel Validation 37 Contact Us 37 Disclaimer 38
List of Tables Richter Gedeon Nyrt., Key Information 5 Richter Gedeon Nyrt., Key Facts 5 Richter Gedeon Nyrt. - Pipeline by Indication, 2015 7 Richter Gedeon Nyrt. - Pipeline by Stage of Development, 2015 8 Richter Gedeon Nyrt. - Monotherapy Products in Pipeline, 2015 9 Richter Gedeon Nyrt. - Pre-Registration, 2015 10 Richter Gedeon Nyrt. - Phase III, 2015 11 Richter Gedeon Nyrt. - Phase II, 2015 12 Richter Gedeon Nyrt. - Preclinical, 2015 13 Richter Gedeon Nyrt. - Discovery, 2015 14 Richter Gedeon Nyrt. - Unknown, 2015 15 Richter Gedeon Nyrt. - Pipeline by Target, 2015 23 Richter Gedeon Nyrt. - Pipeline by Route of Administration, 2015 24 Richter Gedeon Nyrt. - Pipeline by Molecule Type, 2015 25 Richter Gedeon Nyrt. - Pipeline Products by Mechanism of Action, 2015 26 Richter Gedeon Nyrt. - Recent Pipeline Updates, 2015 27 Richter Gedeon Nyrt. - Dormant Developmental Projects,2015 31 Richter Gedeon Nyrt. - Discontinued Pipeline Products, 2015 32 Richter Gedeon Nyrt., Other Locations 34 Richter Gedeon Nyrt., Subsidiaries 35
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.